<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019 (COVID-19) is a pandemic infection caused by Severe"/>
 <result pre="global pandemic. Abstract Coronavirus disease 2019 (COVID-19) is a pandemic" exact="infection" post="caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)."/>
 <result pre="Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects"/>
 <result pre="disease 2019 (COVID-19) is a pandemic infection caused by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple"/>
 <result pre="2019 (COVID-19) is a pandemic infection caused by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems"/>
 <result pre="(COVID-19) is a pandemic infection caused by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including"/>
 <result pre="Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the" exact="cardiovascular" post="system. Most importantly, in addition to the direct injury"/>
 <result pre="anti-SARS-CoV-2 effects, these drugs may also have risks to the" exact="cardiovascular" post="system, especially altering cardiac conduction. Herein, we review the"/>
 <result pre="cardiovascular system, especially altering cardiac conduction. Herein, we review the" exact="cardiovascular" post="risks of potential anti-COVID-19 drugs. Keywords COVID-19 SARS-CoV-2 Potential"/>
 <result pre="Complications Introduction Although there are lacking drugs evident for treating" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), scientists remain attempting"/>
 <result pre="Introduction Although there are lacking drugs evident for treating Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), scientists remain attempting to"/>
 <result pre="Although there are lacking drugs evident for treating Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2), scientists remain attempting to identify"/>
 <result pre="there are lacking drugs evident for treating Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2), scientists remain attempting to identify those"/>
 <result pre="is an international clinical trial searching for an effective Coronavirus" exact="disease" post="2019 (COVID-19) treatment launched by the World Health Organization"/>
 <result pre="are currently regarded as potential anti-SARS-CoV-2 regimens and the documented" exact="cardiovascular" post="risks. Antiviral Drugs Remdesivir Mechanisms By reducing viral replication"/>
 <result pre="the documented cardiovascular risks. Antiviral Drugs Remdesivir Mechanisms By reducing" exact="viral" post="replication and binding to the active site on RNA"/>
 <result pre="[9]. It has been approved for the treatment of Ebola," exact="respiratory" post="syncytial virus (RSV), Junin virus, Lassa fever virus, Nipah"/>
 <result pre="the treatment of Ebola, respiratory syncytial virus (RSV), Junin virus," exact="Lassa fever" post="virus, Nipah virus, Hendra virus, and the coronaviruses (including"/>
 <result pre="were extubated during a median follow-up of 18Â days. A" exact="total" post="of 25 patients (47%) were discharged, and 7 (13%)"/>
 <result pre="is unlikely to increase remdesivir levels. Cardiovascular Risks While extensive" exact="cardiovascular" post="toxicities and drug interactions have not yet been reported,"/>
 <result pre="Ebola outbreak noted that one patient developed hypotension and subsequent" exact="cardiac arrest." post="[13] However, the current evidence indicates that high doses"/>
 <result pre="interval and/or in patients with preexisting risk factors (bradycardia, long" exact="congenital" post="QT, and electrolyte imbalances) [19]. Ritonavir/Lopinavir Mechanisms Ritonavir/lopinavir, a"/>
 <result pre="called Kaletra, was approved in USA in 2000 to treat" exact="HIV infection" post="[20]. With the capability to inhibit the protease of"/>
 <result pre="Kaletra, was approved in USA in 2000 to treat HIV" exact="infection" post="[20]. With the capability to inhibit the protease of"/>
 <result pre="at 28Â days [24]. The percentages of patients with detectable" exact="viral" post="RNA at various time points were similar. However, the"/>
 <result pre="adults [28, 29]. There were rare reports of second- or" exact="third-degree atrioventricular block" post="in patients with underlying structural heart disease and preexisting"/>
 <result pre="[28, 29]. There were rare reports of second- or third-degree" exact="atrioventricular block" post="in patients with underlying structural heart disease and preexisting"/>
 <result pre="second- or third-degree atrioventricular block in patients with underlying structural" exact="heart" post="disease and preexisting conduction system abnormalities [30]. Favipiravir Mechanisms"/>
 <result pre="or third-degree atrioventricular block in patients with underlying structural heart" exact="disease" post="and preexisting conduction system abnormalities [30]. Favipiravir Mechanisms Due"/>
 <result pre="approved to treat influenza [31]. Although one report showed shorter" exact="viral" post="clearance durations and improved chest imaging in patients diagnosed"/>
 <result pre="Although one report showed shorter viral clearance durations and improved" exact="chest" post="imaging in patients diagnosed with COVID-19 compared to controls"/>
 <result pre="China (ChiCTR2000029600) [33]. Based on the anticipated synergistic effect of" exact="viral" post="inhibition and immune enhancement, a randomized control trial (THDMS-COVID-19)"/>
 <result pre="membrane that results in hyperpolarization of ion channels, leading to" exact="muscle" post="paralysis [41]. It is approved for the treatment of"/>
 <result pre="muscle paralysis [41]. It is approved for the treatment of" exact="head lice," post="scabies, strongyloidiasis, trichuriasis, ascariasis, and lymphatic filariasis [42, 43]."/>
 <result pre="the treatment of head lice, scabies, strongyloidiasis, trichuriasis, ascariasis, and" exact="lymphatic filariasis" post="[42, 43]. Beyond its anti-parasite effects, ivermectin has also"/>
 <result pre="treatment of head lice, scabies, strongyloidiasis, trichuriasis, ascariasis, and lymphatic" exact="filariasis" post="[42, 43]. Beyond its anti-parasite effects, ivermectin has also"/>
 <result pre="have revealed a potential role of importin Î±/Î² 1 during" exact="infection" post="[45]. Nuclear transport of viral proteins is essential for"/>
 <result pre="of importin Î±/Î² 1 during infection [45]. Nuclear transport of" exact="viral" post="proteins is essential for the replication cycle and inhibition"/>
 <result pre="in vitro testing revealed its ability to effectively reduce the" exact="viral" post="copy number of SARS-CoV-2 [52]. Several small-scale clinical trials"/>
 <result pre="various degrees of therapeutic effects of HCQ for treating COVID-19-associated" exact="pneumonia" post="[53, 54]. A small open-label non-randomized clinical trial in"/>
 <result pre="a high dose of HCQ could cause serious toxicities including" exact="cardiomyopathy" post="and fatal arrhythmia [7, 8]. Drug Interactions Chloroquine and"/>
 <result pre="of HCQ could cause serious toxicities including cardiomyopathy and fatal" exact="arrhythmia" post="[7, 8]. Drug Interactions Chloroquine and HCQ undergo CYP-mediated"/>
 <result pre="with concomitant QT-prolonging medications such as azithromycin, metabolic derangements, and" exact="renal failure" post="[55]. Of note, hydroxychloroquine has a long half-life of"/>
 <result pre="recommended during this therapy. HCQ also has the potential for" exact="intermediate" post="to delayed myocardial toxicity [8]. Prolonged exposure (&amp;gt;â€‰3Â months)"/>
 <result pre="a higher weight-based dose of HCQ may cause restrictive or" exact="dilated cardiomyopathy," post="especially in patients with preexisting cardiac disease or renal"/>
 <result pre="cause restrictive or dilated cardiomyopathy, especially in patients with preexisting" exact="cardiac disease" post="or renal failure [8]. On April 11, 2020, the"/>
 <result pre="restrictive or dilated cardiomyopathy, especially in patients with preexisting cardiac" exact="disease" post="or renal failure [8]. On April 11, 2020, the"/>
 <result pre="dilated cardiomyopathy, especially in patients with preexisting cardiac disease or" exact="renal failure" post="[8]. On April 11, 2020, the Wall Street Journal"/>
 <result pre="Center in Nice, France, received up to 54 cases developing" exact="cardiovascular" post="complications post-hydroxychloroquine use for the treatment of COVID-19 [57]."/>
 <result pre="6 (IL-6) receptor monoclonal antibody approved for the treatment of" exact="rheumatoid arthritis" post="and systemic juvenile idiopathic arthritis [60, 61]. In a"/>
 <result pre="(IL-6) receptor monoclonal antibody approved for the treatment of rheumatoid" exact="arthritis" post="and systemic juvenile idiopathic arthritis [60, 61]. In a"/>
 <result pre="monoclonal antibody approved for the treatment of rheumatoid arthritis and" exact="systemic" post="juvenile idiopathic arthritis [60, 61]. In a recently published"/>
 <result pre="antibody approved for the treatment of rheumatoid arthritis and systemic" exact="juvenile idiopathic arthritis" post="[60, 61]. In a recently published study of 15"/>
 <result pre="for the treatment of rheumatoid arthritis and systemic juvenile idiopathic" exact="arthritis" post="[60, 61]. In a recently published study of 15"/>
 <result pre="COVACTA, the safety and efficacy of intravenous tocilizumab in hospitalized" exact="adult" post="patients with severe COVID-19 pneumonia will be compared with"/>
 <result pre="of intravenous tocilizumab in hospitalized adult patients with severe COVID-19" exact="pneumonia" post="will be compared with placebo in addition to the"/>
 <result pre="to the findings of the ENTRACTE study that compared the" exact="cardiovascular" post="safety in patients with rheumatoid arthritis receiving either tocilizumab"/>
 <result pre="ENTRACTE study that compared the cardiovascular safety in patients with" exact="rheumatoid arthritis" post="receiving either tocilizumab or etanercept [66], there were no"/>
 <result pre="study that compared the cardiovascular safety in patients with rheumatoid" exact="arthritis" post="receiving either tocilizumab or etanercept [66], there were no"/>
 <result pre="or etanercept [66], there were no significant increases in stroke," exact="heart" post="attack, heart failure hospitalization, or cardiac death. Interferon-Î² Mechanisms"/>
 <result pre="[66], there were no significant increases in stroke, heart attack," exact="heart" post="failure hospitalization, or cardiac death. Interferon-Î² Mechanisms Type 1"/>
 <result pre="heart attack, heart failure hospitalization, or cardiac death. Interferon-Î² Mechanisms" exact="Type 1" post="interferons (IFN-I) play a major role in antiviral immunity"/>
 <result pre="immunomodulatory properties, IFN-Î² is used to treat many diseases, including" exact="multiple sclerosis" post="[68]. When used alone or in combination with other"/>
 <result pre="now focusing on the safety and efficacy for treating COVID-19" exact="pneumonia" post="[73]. SOLIDARITY will also have an arm that combines"/>
 <result pre="observed. Only rare case reports showed premature ventricular captures and" exact="atrioventricular block" post="[75]. Fingolimod (FTY-720) Mechanisms Fingolimod is an oral immunomodulating"/>
 <result pre="oral immunomodulating agent that is primarily used to treat refractory" exact="multiple sclerosis" post="[76]. By structurally resembling the lipid sphingosine-1-phosphate (S1P), fingolimod"/>
 <result pre="[79]. Cardiovascular Risks Given that S1P is crucially involved in" exact="vascular" post="barrier function, coagulation, vascular homeostasis, angiogenesis, and atherosclerosis, Fingolimod"/>
 <result pre="that S1P is crucially involved in vascular barrier function, coagulation," exact="vascular" post="homeostasis, angiogenesis, and atherosclerosis, Fingolimod has been reported to"/>
 <result pre="angiogenesis, and atherosclerosis, Fingolimod has been reported to induce bradyarrhythmia," exact="atrioventricular block," post="and blood pressure through increasing the vascular tone [81,"/>
 <result pre="induce bradyarrhythmia, atrioventricular block, and blood pressure through increasing the" exact="vascular" post="tone [81, 82]. Regarding fingolimod-induced intracellular calcium release and"/>
 <result pre="intracellular calcium release and its consequent contractile effects on smooth" exact="muscle" post="cells, it may cause retinal arterial vasospasm and retinal"/>
 <result pre="smooth muscle cells, it may cause retinal arterial vasospasm and" exact="retinal vein occlusion" post="[76, 81]. Conversely, upon its atheroprotective effects, fingolimod diminishes"/>
 <result pre="occlusion [76, 81]. Conversely, upon its atheroprotective effects, fingolimod diminishes" exact="atherosclerosis" post="plaque volume and macrophage and collagen content in vivo"/>
 <result pre="COVID-19 pandemic. Most importantly, given that patients affected by this" exact="disease" post="commonly have cardiovascular comorbidities, a careful evaluation of the"/>
 <result pre="importantly, given that patients affected by this disease commonly have" exact="cardiovascular" post="comorbidities, a careful evaluation of the possible cardiovascular complications"/>
 <result pre="commonly have cardiovascular comorbidities, a careful evaluation of the possible" exact="cardiovascular" post="complications of these drugs is crucial. Table 1 summarizes"/>
 <result pre="of studies, ongoing clinical trials, drug metabolism, and the possible" exact="cardiovascular" post="complications. Most of the drugs are based on repurposing"/>
 <result pre="remdesivir, favipiravir, ribavirin, and interferon-Î²1 have been less reported with" exact="cardiovascular" post="complications. We believe that this review provides additional cardiovascular"/>
 <result pre="with cardiovascular complications. We believe that this review provides additional" exact="cardiovascular" post="concerns along with the aggressive exploration of candidate drugs"/>
 <result pre="exploration of candidate drugs with anti-SARS-CoV-2 potential. Table 1 The" exact="cardiovascular" post="risks of potential anti-COVID-19 drugs Drugs Pharmacologic mechanism Evidences"/>
 <result pre="transforming to adenosine analogue, causing RNA pre-mature termination and inhibiting" exact="viral" post="replication â€¢ Reducing viral copy numbers in SARS-CoV-2 and"/>
 <result pre="causing RNA pre-mature termination and inhibiting viral replication â€¢ Reducing" exact="viral" post="copy numbers in SARS-CoV-2 and binding to the active"/>
 <result pre="the active site HIV protease and preventing the pro-form of" exact="viral" post="proteins cleaving into the working form. Binding to SARS-CoV-2"/>
 <result pre="statins, ticagrelor, rivaroxaban, and apixaban Liver toxicity, pancreatitis, GI upset," exact="neurotoxicity" post="22, 26, 28, 29, 33, 42, 73 Â Â"/>
 <result pre="33, 42, 73 Â Â Favipiravir A selective inhibition of" exact="viral" post="RNA-dependent RNA polymerase Suppressing viral RNA-dependent RNA polymerase of"/>
 <result pre="Favipiravir A selective inhibition of viral RNA-dependent RNA polymerase Suppressing" exact="viral" post="RNA-dependent RNA polymerase of SARS-CoV-2; in vitro? Influenza viruses,"/>
 <result pre="polymerase of SARS-CoV-2; in vitro? Influenza viruses, West Nile virus," exact="yellow fever" post="virus, foot-and-mouth disease virus NCT04303299 (THDMS-COVID-19); NCT04310228; ChiCTR2000029600 (plus"/>
 <result pre="vitro? Influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth" exact="disease" post="virus NCT04303299 (THDMS-COVID-19); NCT04310228; ChiCTR2000029600 (plus IFN-Î±) Only a"/>
 <result pre="Not reported 34â€&quot;38 Â Â Ribavirin A nucleoside inhibitor, stopping" exact="viral" post="RNA synthesis and mRNA capping Binding to the active"/>
 <result pre="RNA polymerase on SARS-CoV-2; in vitro? HCV, RSV and some" exact="viral" post="hemorrhagic fevers NCT04276688 No report of cytochrome P450 enzyme"/>
 <result pre="toxicity; ribavirin has variable effects on warfarin dosing Liver toxicity," exact="hematologic disorder" post="40, 43, 44 Â Â Ivermectin An influx of"/>
 <result pre="in vitro study Head lice, scabies, strongyloidiasis, trichuriasis, ascariasis, and" exact="lymphatic filariasis" post="Not yet lunched An inducer of several cytochrome P450"/>
 <result pre="vitro study Head lice, scabies, strongyloidiasis, trichuriasis, ascariasis, and lymphatic" exact="filariasis" post="Not yet lunched An inducer of several cytochrome P450"/>
 <result pre="with the glycosylation of its cellular receptor, ACE2; reduce the" exact="viral" post="copy number of SARS-CoV-2. Reducing viral copy numbers in"/>
 <result pre="receptor, ACE2; reduce the viral copy number of SARS-CoV-2. Reducing" exact="viral" post="copy numbers in SARS-CoV-2; Under debates between China and"/>
 <result pre="SARS-CoV-2; Under debates between China and France? Anti-malaria. Treatment of" exact="rheumatoid arthritis," post="lupus, and porphyria cutanea tarda NCT04286503 NCT04303507 NCT04307693 NCT04261517"/>
 <result pre="China and France? Anti-malaria. Treatment of rheumatoid arthritis, lupus, and" exact="porphyria" post="cutanea tarda NCT04286503 NCT04303507 NCT04307693 NCT04261517 NCT04303299 NCT04334512 More"/>
 <result pre="More than 50 ongoing trials combined with Zithromax, vitamin, zinc" exact="Metabolism" post="by CYPs 2C8, 3A4 and 2D6 (increased concentration beta-blockers)"/>
 <result pre="2D6 (increased concentration beta-blockers) Intermediate-to-delayed cardiotoxicity 1. Direct: restrictive or" exact="dilated cardiomyopathy" post="2. Altered conduction: AV block, bundle branch block, torsade"/>
 <result pre="(increased concentration beta-blockers) Intermediate-to-delayed cardiotoxicity 1. Direct: restrictive or dilated" exact="cardiomyopathy" post="2. Altered conduction: AV block, bundle branch block, torsade"/>
 <result pre="cardiotoxicity 1. Direct: restrictive or dilated cardiomyopathy 2. Altered conduction:" exact="AV block," post="bundle branch block, torsade de pointes, ventricular tachycardia/fibrillation Neutropenia,"/>
 <result pre="Â Tocilizumab Anti-IL-6 receptor monoclonal antibody Anti-cytokine storm? In vitro?" exact="Rheumatoid arthritis," post="juvenile idiopathic arthritis. NCT04306705 (TACOS); NCT04320615 (COVACTA) Reversal of"/>
 <result pre="Anti-IL-6 receptor monoclonal antibody Anti-cytokine storm? In vitro? Rheumatoid arthritis," exact="juvenile idiopathic arthritis." post="NCT04306705 (TACOS); NCT04320615 (COVACTA) Reversal of IL-6 inducing suppression"/>
 <result pre="Hypertension, increased serum cholesterol; no known effect on QTc interval" exact="Allergic" post="reaction, susceptible to infection 62â€&quot;68 Â Â Interferon-Î²1 A"/>
 <result pre="no known effect on QTc interval Allergic reaction, susceptible to" exact="infection" post="62â€&quot;68 Â Â Interferon-Î²1 A cytokine produced by innate"/>
 <result pre="immune cells, including macrophages, dendritic cells, and non-immune cells Recognizing" exact="viral" post="components by pattern recognition receptors (PRR) (Liu, 2005) Multiple"/>
 <result pre="Recognizing viral components by pattern recognition receptors (PRR) (Liu, 2005)" exact="Multiple" post="sclerosis NCT04293887 Reduce the activity of hepatic cytochrome P450-dependent"/>
 <result pre="As an effective immunology modulator, fingolimod with potentials of anti-SARS-CoV-2" exact="Multiple" post="sclerosis, refractory NCT04280588 Metabolism by CYP4F2. Us in caution"/>
 <result pre="modulator, fingolimod with potentials of anti-SARS-CoV-2 Multiple sclerosis, refractory NCT04280588" exact="Metabolism" post="by CYP4F2. Us in caution when combined with class"/>
 <result pre="anti-arrhythmic agents and beta-blockers Pros: Arthero-protection, anti-hypertrophy Cons: Bradycardia, AVB," exact="hypertension" post="Liver toxicity, headache, GI upset, flu-like symptoms 80â€&quot;84 The"/>
 <result pre="drugs involved with COVID-19 CV cardiovascular, GI gastrointestinal, SARS-CoV-2 severe" exact="acute" post="respiratory syndrome coronavirus 2, RNA ribonucleic acid, RSV respiratory"/>
 <result pre="involved with COVID-19 CV cardiovascular, GI gastrointestinal, SARS-CoV-2 severe acute" exact="respiratory" post="syndrome coronavirus 2, RNA ribonucleic acid, RSV respiratory syncytial"/>
 <result pre="with COVID-19 CV cardiovascular, GI gastrointestinal, SARS-CoV-2 severe acute respiratory" exact="syndrome" post="coronavirus 2, RNA ribonucleic acid, RSV respiratory syncytial virus,"/>
 <result pre="severe acute respiratory syndrome coronavirus 2, RNA ribonucleic acid, RSV" exact="respiratory" post="syncytial virus, HIV human immunodeficiency virus, HPV human papillomavirus,"/>
 <result pre="2, RNA ribonucleic acid, RSV respiratory syncytial virus, HIV human" exact="immunodeficiency" post="virus, HPV human papillomavirus, AVB atrioventricular block #Clinical trials"/>
 <result pre="syncytial virus, HIV human immunodeficiency virus, HPV human papillomavirus, AVB" exact="atrioventricular block" post="#Clinical trials summarized here till April 13, 2020 Fig."/>
 <result pre="here till April 13, 2020 Fig. 1 The illustration of" exact="cardiovascular" post="concerns of potential anti-COVID-19 drugs Publisherâ€™s Note Springer Nature"/>
 <result pre="patients, health care workers, and health systems during the coronavirus" exact="disease" post="2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75:2352â€&quot;71. 7.ChenC-YWangF-LLinC-CChronic"/>
 <result pre="rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature reviewEur" exact="Heart" post="J Acute Cardiovasc Care201321778310.1177/204887261247121524062937 9.Gordon CJ, Tchesnokov EP, Feng"/>
 <result pre="biventricular cardiomyopathy: key diagnostic features and literature reviewEur Heart J" exact="Acute" post="Cardiovasc Care201321778310.1177/204887261247121524062937 9.Gordon CJ, Tchesnokov EP, Feng JY, Porter"/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem. 2020;295(15):4773â€&quot;9. 10.Tchesnokov EP, Feng"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem. 2020;295(15):4773â€&quot;9. 10.Tchesnokov EP, Feng JY,"/>
 <result pre="B, Phiri A, Kondowe M, Piston W, et al. Human" exact="immunodeficiency" post="virus, antiretroviral therapy and markers of lymphatic filariasis infection:"/>
 <result pre="et al. Human immunodeficiency virus, antiretroviral therapy and markers of" exact="lymphatic filariasis" post="infection: a cross-sectional study in rural Northern Malawi. PLoS"/>
 <result pre="al. Human immunodeficiency virus, antiretroviral therapy and markers of lymphatic" exact="filariasis" post="infection: a cross-sectional study in rural Northern Malawi. PLoS"/>
 <result pre="of atazanavir on the QTc interval and QTc dispersion in" exact="HIV-positive" post="patients. HIV Med. 2006;7(5):317â€&quot;22. 18.Gallagher DP, Kieran J, Sheehan"/>
 <result pre="therapy. Clin Infect Dis. 2007;44(6):e67â€&quot;8. 20.FengH-PCaroLFandozziCChuXGuoZTalatyJet al.Pharmacokinetic interactions between the" exact="hepatitis C" post="virus inhibitors elbasvir and grazoprevir and HIV protease inhibitors"/>
 <result pre="T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymerase. Proc Jpn Acad Ser B Phys Biol"/>
 <result pre="and efficacy of Favipiravir in the treatment of novel coronavirus" exact="pneumonia" post="(COVID-19). 2020;ChiCTR2000029600. 34.Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir,"/>
 <result pre="favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of" exact="viral" post="hemorrhagic fever. Antivir Res. 2015;121:132â€&quot;7. 36.Chinello P, Petrosillo N,"/>
 <result pre="application and mechanism of action of ribavirin in therapy of" exact="hepatitis C." post="Antivir Chem Chemother. 2012;23(1):1â€&quot;12. 38.Jin YH, Cai L, Cheng"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Mil Med Res. 2020;7(1):4. 39.Goodarzi N, Barazesh"/>
 <result pre="R, MacLaren D, et al. Impact of ivermectin administered for" exact="scabies" post="treatment on the prevalence of head lice in Atoifi"/>
 <result pre="of ivermectin administered for scabies treatment on the prevalence of" exact="head lice" post="in Atoifi Solomon Islands. PLoS Negl Trop Dis. 2018;12(9):e0006825."/>
 <result pre="and albendazole for treatment of intestinal helminth and Wuchereria bancrofti" exact="infections" post="in Haitian schoolchildren. Am J Trop Med Hyg. 1999;60(3):479â€&quot;86."/>
 <result pre="Bonnetblanc JM, Peyrot I, Loustaud-Ratti V, Vidal E, Bedane C." exact="Systemic" post="adverse reactions with ivermectin treatment of scabies. Ann Dermatol"/>
 <result pre="Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for" exact="cancer" post="therapy. Mol Cell Oncol. 2014;1(1):e29911. 50.Schrezenmeier E, Dorner T."/>
 <result pre="et al. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. 2005;2:69. 52.Liu J, Cao R,"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell Discov. 2020;6:16. 53.Sahraei Z, Shabani M,"/>
 <result pre="Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus" exact="disease" post="2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents."/>
 <result pre="Yavari A, Mirams GR, Douglas G, et al. Hydroxychloroquine reduces" exact="heart" post="rate by modulating the hyperpolarization-activated current If: Novel electrophysiological"/>
 <result pre="the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential." exact="Heart" post="Rhythm. 2015;12(10):2186â€&quot;94. 56.Tett SE, Cutler DJ, Day RO, Brown"/>
 <result pre="anti-interleukin 6 receptor antibody for the treatment of patients with" exact="rheumatoid arthritis." post="Ther Adv Musculoskelet Dis. 2011;3(3):133â€&quot;49. 61.Yokota S, Itoh Y,"/>
 <result pre="Origasa H, Sumitomo N, Tomobe M, et al. Tocilizumab in" exact="systemic" post="juvenile idiopathic arthritis in a real-world clinical setting: results"/>
 <result pre="H, Sumitomo N, Tomobe M, et al. Tocilizumab in systemic" exact="juvenile idiopathic arthritis" post="in a real-world clinical setting: results from 1 year"/>
 <result pre="N, Tomobe M, et al. Tocilizumab in systemic juvenile idiopathic" exact="arthritis" post="in a real-world clinical setting: results from 1 year"/>
 <result pre="S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with" exact="rheumatoid arthritis." post="Clin Pharmacol Ther. 2011;89(5):735â€&quot;40. 65.Cacciapaglia F, Anelli MG, Rinaldi"/>
 <result pre="Scioscia C, et al. Lipids and atherogenic indices fluctuation in" exact="rheumatoid arthritis" post="patients on long-term tocilizumab treatment. Mediat Inflamm. 2018;2018:2453265. 66.Giles"/>
 <result pre="C, et al. Lipids and atherogenic indices fluctuation in rheumatoid" exact="arthritis" post="patients on long-term tocilizumab treatment. Mediat Inflamm. 2018;2018:2453265. 66.Giles"/>
 <result pre="tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial." exact="Arthritis" post="Rheum. 2020;72(1):31â€&quot;40. 67.Murira A, Lamarre A. Type-I interferon responses:"/>
 <result pre="interferon responses: from friend to foe in the battle against" exact="chronic" post="viral infection. Front Immunol. 2016;7:609. 68.Panitch HS, Bever CT"/>
 <result pre="responses: from friend to foe in the battle against chronic" exact="viral infection." post="Front Immunol. 2016;7:609. 68.Panitch HS, Bever CT Jr. Clinical"/>
 <result pre="68.Panitch HS, Bever CT Jr. Clinical trials of interferons in" exact="multiple sclerosis." post="What have we learned? J Neuroimmunol. 1993;46(1â€&quot;2):155â€&quot;64. 69.Hijano DR,"/>
 <result pre="Kauvar LM, Tripp RA, Polack FP, Cormier SA. Role of" exact="type I" post="interferon (IFN) in the respiratory syncytial virus (RSV) immune"/>
 <result pre="Cormier SA. Role of type I interferon (IFN) in the" exact="respiratory" post="syncytial virus (RSV) immune response and disease severity. Front"/>
 <result pre="(IFN) in the respiratory syncytial virus (RSV) immune response and" exact="disease" post="severity. Front Immunol. 2019;10:566. 70.Sallard E, Lescure FX, Yazdanpanah"/>
 <result pre="Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, Committee CDFS." exact="Type 1" post="interferons as a potential treatment against COVID-19. Antivir Res."/>
 <result pre="Farrell GC. Interferon gamma down-regulates cytochrome P450 3A genes in" exact="primary" post="cultures of well-differentiated rat hepatocytes. Hepatology. 1996;24(2):367â€&quot;73. 75.Teragawa H,"/>
 <result pre="Hino F, Ohbayashi M. Adverse effects of interferon on the" exact="cardiovascular" post="system in patients with chronic hepatitis C. Jpn Heart"/>
 <result pre="effects of interferon on the cardiovascular system in patients with" exact="chronic hepatitis C." post="Jpn Heart J. 1996;37(6):905â€&quot;15. 76.ChunJBrinkmannVA mechanistically novel, first oral"/>
 <result pre="of interferon on the cardiovascular system in patients with chronic" exact="hepatitis C." post="Jpn Heart J. 1996;37(6):905â€&quot;15. 76.ChunJBrinkmannVA mechanistically novel, first oral"/>
 <result pre="the cardiovascular system in patients with chronic hepatitis C. Jpn" exact="Heart" post="J. 1996;37(6):905â€&quot;15. 76.ChunJBrinkmannVA mechanistically novel, first oral therapy for"/>
 <result pre="A, et al. 6-Month effects of fingolimod on indexes of" exact="cardiovascular" post="autonomic control in multiple sclerosis. J Am Coll Cardiol."/>
 <result pre="effects of fingolimod on indexes of cardiovascular autonomic control in" exact="multiple sclerosis." post="J Am Coll Cardiol. 2016;68(18):2027â€&quot;9. 83.Egom EE, Mohamed TM,"/>
 <result pre="mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol" exact="Heart" post="Circ Physiol. 2011;301(4):H1487â€&quot;95."/>
</results>
